

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of AUG 06 2002

Von Wronski et al.

Serial No. 09/871,974

Filed: June 4, 2001

Atty. Ref.: 2238-7

Group: 1653

Examiner: (Unassigned)

For: COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS,
COMPOSITIONS CONTAINING THE SAME AND
METHODS FOR THEIR USE

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

August 6, 2002

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each
identified document and a translation or a concise explanation of

each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 9 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Von Wronski et al.
Serial No. 09/871,974

Respectfully submitted,
NIXON & VANDERHYE P.C.

By:

A handwritten signature in black ink, appearing to read "B. J. Sadoff", written over a horizontal line.

B. J. Sadoff
Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

2238-7

APPLICANT

Von Wronski et al.

FILING DATE

June 4, 2001

SERIAL NO.

09/871,974

GROUP

1653

U.S. PATENT DOCUMENTS

RECEIVED
AUG 07 2002
TECH CENTER 1600/2900

OIPET

(Use several sheets if necessary)

AUG 06 2002

PATENT & TRADEMARK OFFICE

433437

NER

AL

DOCUMENT N

*EXAMINER
INITIAL

TRADEMARK ELEMENT NUMBER

DATE _____

NAME

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE

5,659,041

08/1997

POLLAK, et al.

FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT

DATE _____

COUNTRY

CLASS

SUBCLASS

YES

NO

WO 01/98294 A2

12/2001

PCT

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

4. R. Dunn-Dufault, et al, Convenient Preparation of No-Carrier-Added-Technetium-99m Radiopharmaceuticals Using Solid-Phase Technology, 1999, pages 832-837, vol. 10, XP002200847 Washington US; abstract; figures 1,2

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)